FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
dc.contributor.author | Chllamma, M | |
dc.contributor.author | Cook, Natalie | |
dc.contributor.author | Dhani, N | |
dc.contributor.author | Giby, K | |
dc.contributor.author | Dodd, A | |
dc.contributor.author | Wang, L | |
dc.contributor.author | Hedley, D | |
dc.contributor.author | Moore, M | |
dc.contributor.author | Knox, J | |
dc.date.accessioned | 2016-10-12T13:04:00Z | |
dc.date.available | 2016-10-12T13:04:00Z | |
dc.date.issued | 2016-09-06 | |
dc.identifier.citation | FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. 2016, 115 (6):649-54 Br J Cancer | en |
dc.identifier.issn | 1532-1827 | |
dc.identifier.pmid | 27467054 | |
dc.identifier.doi | 10.1038/bjc.2016.222 | |
dc.identifier.uri | http://hdl.handle.net/10541/619940 | |
dc.description.abstract | FOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to British journal of cancer | en |
dc.title | FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. | en |
dc.type | Article | en |
dc.contributor.department | Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto | en |
dc.identifier.journal | British Journal of Cancer | en |
html.description.abstract | FOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre. |